Industry / South Africa

Cipla Medpro Upgraded Plant Offers Positive Future Revenues

March 2010 | Industry Trend Analysis

Printable version
Bookmark

South African drugmaker Cipla Medpro is still restructuring its manufacturing site in the country, lending optimism to its overall growth strategy.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

HIV Rate Significantly Above Expectations

Industry / South Africa BMI View: Although South Africa's anti-HIV/AIDS strategy appears to be in trouble - as the prevalence rate is far higher than expected - it is possible that part of this growth could be attributed to people...

July 2011

Black Economic Empowerment Rules Extended For All Public Procurements

Industry / South Africa BMI View: Most South African drugmakers have already made an effort to attain a high black economic empowerment (BEE) rating and have welcomed alterations to the drug tender regulations. The extension...

June 2011

Aspen Releases Positive Results

Industry / South Africa South African drugmaker Aspen has released positive financial results for 2009, highlighting its key growth drivers as the GlaxoSmithKline (GSK) interdependent transactions, which have given Aspen the...

March 2010

Generic Drugs Making Progress In Market Share By Value

Industry / South Africa The South African pharmaceutical market is expected to comprise US$2.0bn worth of patented drugs by 2014, underlining our cautious medium-term view that the government will be slow to improve access...

March 2010

New Policy To Affect Pharmaceutical Trade

Industry / South Africa South Africa's largest drugmakers have responded positively to the new trade policy that will lower antiretroviral (ARV) medicine prices in the country. Local manufacturers will be able to lower prices...

March 2010